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Abstract 
Guillain-Barré syndrome (GBS) has been reported in HIV-infected patients in association 
with the immune reconstitution syndrome whose symptoms can be mimicked by highly 
active antiretroviral therapy (HAART)-mediated mitochondrial toxicity. We report a case 
of a 17-year-old, HIV-infected patient on HAART with a normal CD4 count and 
undetectable viral load, presenting with acute lower extremity weakness associated with 
lactatemia. Electromyography/nerve conduction studies revealed absent sensory 
potentials and decreased compound muscle action potentials, consistent with a 
diagnosis of acute motor and sensory axonal neuropathy. Lactatemia resolved following 
cessation of HAART; however, neurological deficits minimally improved over several 
months in spite of immune modulatory therapy. This case highlights the potential 
association between HAART, mitochondrial toxicity and acute axonal neuropathies in 
HIV-infected patients, distinct from the immune reconstitution syndrome. 
Introduction 
Guillain-Barré syndrome (GBS) is an acute peripheral neuropathy classified into at 
least four subgroups by electrodiagnostic criteria, pathology, and anti-ganglioside 
antibody profiles [1]. GBS has been reported in patients with primary HIV infection, 
although this is not commonly observed [2]. In HIV-infected patients, GBS has been 
reported in association with the immune reconstitution syndrome, whereby there is a re-
emergence of previously anergic lymphocytes upon viral suppression with highly active 
antiretroviral therapy (HAART) [3–7]. Nucleoside analogue reverse transcriptase  
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inhibitors (NRTIs), a key component of HAART, have been related to GBS in HIV-
infected individuals in association with the immune reconstitution syndrome [8–10]. 
Bristol-Myers Squibb reported 22 cases of GBS associated with stavudine therapy, each 
with lactatemia, resulting in 7 deaths [10]. We report a case of an HIV-infected adolescent 
presenting with subacute weakness and lactatemia, diagnosed with acute motor and 
sensory axonal neuropathy (AMSAN) following long-term HAART therapy, distinct 
from the immune reconstitution syndrome. 
Case Report 
A 17-year-old female with HIV secondary to a blood transfusion during infancy presented after a fall 
at home. The patient complained of generalized weakness for 4–5 days prior to admission that resulted 
in a buttock abscess. Pertinent past medical history includes HIV-associated pulmonary hypertension, 
cardiomyopathy, sensorineural hearing loss, major depressive disorder, and complex partial epilepsy. 
Her antiretroviral regimen included stavudine, abacavir, ritonavir, and lopinavir that were administered 
by a caretaker daily for several years. She underwent frequent follow-up assessments in the HIV clinic, 
with routine periodic viral load and CD4 lymphocyte monitoring. 
On neurological examination, the patient was alert and oriented to person, time and place, with a 
depressed affect. Cranial nerves 1–12 were intact. There was marked pitting edema of the hands and 
feet, with greater distal than proximal weakness of the upper (3/5) and lower extremities (2/5) 
bilaterally. Patellar and Achilles reflexes were 1+ bilaterally. Sensation to pain and temperature and joint 
position sense were normal. The patient was unable to ambulate independently due to the profound 
weakness. She received normal saline intravenously for tachycardia, and broad-spectrum antibiotics 
were initiated for suspected sepsis secondary to her buttock abscess. Laboratory tests revealed a 
complete blood count of 19.2 with 41 bands, and an elevated serum lactate level (13.5 mmol/l). The 
patient had a CD4 count of 392 cells/mm
3 and an undetectable viral load (table 1). Results from a 
lumbar puncture were within normal limits for white blood cells, red blood cells, glucose, and protein 
levels. Cerebrospinal fluid studies were negative for herpesvirus 1/2, Epstein-Barr virus, 
cytomegalovirus, and Treponema pallidum. Magnetic resonance imaging of the brain and spine with 
and without gadolinium showed normal findings. All antiretroviral medications were discontinued due 
to the lactatemia, concerning for possible mitochondrial toxicity. Electromyogram (EMG) and nerve 
conduction studies (NCS) revealed numerous abnormalities, leading to the final diagnosis of AMSAN 
(table 2). First, there were absent sensory nerve action potentials in the medial, ulnar, sural, medial 
plantar, and superficial peroneal nerves. Second, very low compound muscle action potentials (CMAPs) 
were recorded at the median, peroneal, and tibial nerves, with absent CMAPs of the ulnar nerve. F wave 
studies showed prolonged distal latencies, with relative sparing of nerve conduction velocities. Finally, 
EMG elicited positive sharp waves and fibrillations. The constellation of EMG and NCS findings were 
consistent with a diagnosis of AMSAN. The patient was empirically treated with intravenous 
immunoglobulin (0.4 mg/kg/day) for 5 days but failed to show significant improvement in her distal 
extremity weakness in spite of a normalized lactate level. 
Three months after discharge, the patient had minor improvements in strength of her distal upper 
extremities (4/5) when compared to distal lower extremities (2/5), and was still unable to ambulate 
independently. 
Discussion 
The classical GBS variants follow an infectious prodrome, resulting in an augmented 
immune response which cross-reacts with axolemmal or Schwann cell antigens, leading to 
peripheral nerve damage via molecular mimicry [1]. GBS may occur in HIV-infected 
patients at the time of seroconversion or, more commonly, in the setting of the immune 
reconstitution syndrome [3–5, 7]. The immune recovery phase, evidenced by an increase 
in the CD4 lymphocyte count and a decrease in the HIV viral load, is presumptively  
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responsible for the neuroimmune-mediated attack. While other cases of GBS associated 
with lactic acidosis related to HAART have been reported [8, 11], this is the first case of 
GBS, AMSAN in particular, occurring in the absence of the immune reconstitution 
syndrome. Although impossible to prove conclusively, the most likely mechanism of 
AMSAN in our patient was HAART-associated mitochondrial toxicity. This is evidenced 
by an acute lactatemia, in the absence of any other etiology, which resolved upon 
cessation of antiretroviral therapies. The confounding buttock abscess observed on 
examination would be another potential source of lactatemia; however, the abrupt 
cessation of HAART showed immediate and sustained decrease in the serum lactate level, 
consistent with a hypothesis of a HAART-related phenomenon. Given the patient’s 
tremendous amount of comorbities, including cardiomyopathy, sensorineural hearing 
loss, and pulmonary hyptertension, an underlying previous undiagnosed mitochondrial 
cytopathy could also explain the patient’s symptomatology. However, mitochondrial 
DNA testing was performed at admission which was unrevealing. A pre-existing or 
acquired mitochondrial cytopathy cannot be completely ruled out since the entire nuclear 
and mitochondrial genomes were not sequenced. Given the numerous reports of 
HAART-related mitochondrial toxicity in HIV-infected patients, we believe a subset of 
patients may have HIV- or drug-induced mitochondrial toxicity as opposed to an 
underlying mitochondrial cytopathy prior to diagnosis. 
HAART-related mitochondrial toxicity has been associated with lactatemia and death, 
particularly in the case of stavudine [10]. Chronic stavudine use, in addition to lactatemia, 
has been associated with Miller Fisher syndrome in one case report [8]. It is hypothesized 
that NRTIs, in particular zidovudine, induce myotoxicity via oxidative stress, inhibition of 
the mitochondrial machinery, and L-carnitine deficiency [9]. NRTIs may alter the 
function of the mitochondrial enzyme DNA polymerase gamma, leading to dysfunction 
or depletion in addition to HIV-induced mitochondrial toxicity [12]. Stavudine has been 
hypothesized to mimic GBS via the inhibition of the mitochondrial polymerase gamma 
enzyme [13]. Other HAARTs are likely to affect the mitochondrial machinery via similar 
mechanisms, as opposed to altering the nuclear to mitochondrial DNA ratios, which has 
been shown to be an ineffective marker of HAART-associated mitochondrial toxicity 
[14]. 
One possible treatment of HAART-associated GBS is stabilization of the mitochondria 
via carnitine therapy. Unfortunately, in our patient, total and free carnitine levels were 
not measured and vitamin/cofactor therapies were not utilized. These would have been 
reasonable therapeutic options as the patient responded only minimally to intravenous 
immunoglobulin treatment, supporting a role of therapy-induced mitochondrial toxicity 
in addition to an immune-mediated pathophysiology. To further support a neuroimmune 
mechanism of the disease, IgG anti-ganglioside antibodies to GM1, GM1b, and GD1a 
may have been useful in the disease classification.
 Plasmaphoresis, a common therapeutic 
modality for AMSAN, was not attempted in our patient because of her higher procedural 
risk secondary to severe HIV-related chronic pulmonary hypertension and 
cardiomyopathy. 
Conclusion 
Clinicians should be aware that GBS variants can occur in both adult and pediatric 
HIV patients on chronic HAART in the absence of an immune reconstitution syndrome.  
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Both mitochondrial toxicity (evidenced by elevated serum lactate) and neuroimmune 
mechanisms may play a role in disease pathogenesis.  
 
 
 
Table 1. Laboratory values 
  0Results Normal  values 
Hematology 
WBC, K/mcl 
Bands, % 
Segs, % 
0 
00.19.2 
00.41 
.0030 
 
4.19–9.43 
00.0–1 
.045–76 
Lymphocytes, % 
Monocytes, % 
Hemoglobin, g/dl 
Platelets, K/mcl 
CD4, cells/mm
3 
HIV viral load, copies/ml 
Chemistry 
Na, mmol/l 
K+, mmol/l 
Cl–, mmol/l 
Blood urea nitrogen, mg/dl 
Creatinine, mg/dl 
Albumin, g/dl 
Alkaline phosphatase, u/l 
Direct bilirubin, mg/dl 
Total bilirubin, mg/dl 
Aspartate aminotransferase, u/l 
Alanine aminotransferase, u/l 
Lactate, mmol/l 
Pyruvate, mg/dl 
Coagulation 
PT, s 
PTT, s 
INR 
Cerebrospinal fluid 
WBC, /μl 
RBC, /μl 
Protein, mg/dl 
Glucose, mg/dl 
CMV PCR 
EBV 
HSV-1, HSV-2 
VDRL 
Other 
Valproic acid, mg/μl 
Ammonia, μmol/l 
Thyroid-stimulating hormone, μu/ml 
B12, pg/ml 
Free T4, ng/dl 
RPR 
00.15 
.0009 
00.10.1 
0.309 
.0392 
000.0 
 
.0131 
.0003.9 
00.91 
.0004 
.0000.5 
.0003.6 
00.94 
.0002.74 
.0003.8 
00.46 
.0014 
00.13.5 
.0001.67 
 
00.16.5 
00.30 
.0001.4 
 
000.1  
.0001  
00.31 
.0093 
negative 
negative 
negative 
non reactive 
 
00.56 
.0024 
.0003.40  
1,892 
.0001.94 
NR 
0.14–41 
.004–8 
10.8–13.3 
.194–345 
.500–1,500 
.000 
 
.133–143 
03.3–4.7 
0.97–107 
.007–21 
00.5–1.1 
03.8–5.6 
0.82–169 
0 <0.4 
0 <0.8 
.000–26 
0.19–49 
.001–2.4 
00.3–1.5 
 
11.5–13.8 
22.3–34.4 
00.8–1.1 
 
00.0–6  
.000  
0.15–45 
.041–84 
 
 
 
 
 
0.50–100 
.029–54 
0.51–4.91 
.210–911 
01.1–1.6 
NR 
 
  
Case Rep Neurol 2011;3:1–6 
DOI: 10.1159/000322573 
Published online: 
January 11, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
5
Table 2. Summary of electromyogram and nerve conduction studies 
Nerve, location  Amplitude 
mV 
Distance  
cm 
Latency  
ms 
Conduction  
velocity, m/s 
         
Motor nerve conduction studies 
Ulnar, wrist  0  07              
Ulnar,  below  elbow  0  20              
Ulnar,  above  elbow  0  10              
Median, wrist    00.1  06  04.40           
Median, elbow  0.1  20  07.90  57.1           
Peroneal, ankle  0.3  06  05.00             
Peroneal,  fibula  0.4  30 13.10  37.0           
Peroneal, knee  0.2  08 15.45  34.0           
Tibial,  knee  0.3  30 14.90             
Nerve, location  Distance 
cm 
Response              
Sensory nerve conduction studies 
Median,  wrist  13  None               
Ulnar,  wrist  11  None               
Sural,  calf  12  None               
Superior peroneal, lateral  12  None                 
Medial plantar, sole  14  None               
Spontaneous MUAP     Nerve 
IA FIB  PSW  FASC  HFD    AMP  DUR  PPP   
Recruitment
Electromyogram studies                   
Tibialis  anterior  3+  3+ 3+ 0 0   0 0 0    None 
Gastrocnemius    3+  3+ 3+ 0 0   0 0 0    None 
Vastus  lateralis  3+  3+ 3+ 0 0   0 0 0    None 
Biceps  1+  1+ 1+ 0 0   0 0 1+    Reduced 
Deltoid  1+  0  0  0 0   0 0 0    Reduced 
First  dorsal  interosseus  3+  3+ 2+ 0 0   0 0 0    None 
MUAP = Motor unit action potential; IA = insertional activity; FIB = fibrillations; PSW = positive sharp waves; FASC = 
fasciculations; HFD = high-frequency discharges; AMP = amplitude; DUR = duration; PPP = polyphasic potentials. 
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